Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting α‐Synuclein
Poul Henning Jensen, Michael G. Schlossmacher, Leonidas Stefanis
Movement Disorders (2023) Vol. 38, Iss. 3, pp. 378-384
Open Access | Times Cited: 20

Showing 20 citing articles:

Alpha Synuclein: Neurodegeneration and Inflammation
Gianluigi Forloni
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5914-5914
Open Access | Times Cited: 57
Experimental Animal Models of Prodromal Parkinson’s Disease
Hodaka Yamakado, Ryōsuke Takahashi
Journal of Parkinson s Disease (2024) Vol. 14, Iss. s2, pp. S369-S379
Open Access | Times Cited: 12
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial
Pepijn Eijsvogel, Pinaki Misra, Luis Concha‐Marambio, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2631-2640
Open Access | Times Cited: 8
Biomarkers for Managing Neurodegenerative Diseases
Lara Cheslow, Adam E. Snook, Scott A. Waldman
Biomolecules (2024) Vol. 14, Iss. 4, pp. 398-398
Open Access | Times Cited: 5
Objective measurement versus clinician-based assessment for Parkinson’s disease
Andrea Guerra, Valentina D’Onofrio, Florinda Ferreri, et al.
Expert Review of Neurotherapeutics (2023) Vol. 23, Iss. 8, pp. 689-702
Closed Access | Times Cited: 12
Biomimetic nanodecoys deliver cholesterol-modified heteroduplex oligonucleotide to target dopaminergic neurons for the treatment of Parkinson's disease
Si Huang, Yongjiang Li, Junyong Wu, et al.
Acta Biomaterialia (2024) Vol. 177, pp. 316-331
Open Access | Times Cited: 4
Prasinezumab slows motor progression in Parkinsons disease: beyond the clinical data
Bin Xiao, Eng‐King Tan
npj Parkinson s Disease (2025) Vol. 11, Iss. 1
Open Access
A personalised and comprehensive approach is required to suppress or replenish SNCA for Parkinson’s disease
Dunhui Li, Wai Yan Yau, Shengdi Chen, et al.
npj Parkinson s Disease (2025) Vol. 11, Iss. 1
Open Access
Development of a simplified smell test to identify Parkinson’s disease using multiple cohorts, machine learning and item response theory
Juan Li, Kelsey F. Grimes, Joseph Saade, et al.
npj Parkinson s Disease (2025) Vol. 11, Iss. 1
Open Access
From past to future: Digital approaches to success of clinical drug trials for Parkinson's disease
Cen Cong, Madison Milne‐Ives, Ananya Ananthakrishnan, et al.
Journal of Parkinson s Disease (2025)
Open Access
Alpha-synuclein and the Parkinson's disease drug pipeline
Alberto J. Espay, Kevin McFarthing
Parkinsonism & Related Disorders (2023) Vol. 111, pp. 105432-105432
Closed Access | Times Cited: 10
Protective mechanisms by glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor against the α-synuclein accumulation in Parkinson's disease
Şafak Er, Mikko Airavaara
Biochemical Society Transactions (2023) Vol. 51, Iss. 1, pp. 245-257
Closed Access | Times Cited: 7
Antibodies and α-synuclein: What to target against Parkinson's Disease?
Daniel E. Otzen
Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics (2023) Vol. 1872, Iss. 2, pp. 140943-140943
Open Access | Times Cited: 5
Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model
Hugo Geerts, Silke Bergeler, Mike Walker, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Human serum-derived α-synuclein auto-antibodies mediate NMDA receptor-dependent degeneration of CNS neurons
Pretty Garg, Franziska Würtz, Fabian Hobbie, et al.
Journal of Neuroinflammation (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 1
Development of a Simplified Smell Test to Identify Patients with Typical Parkinson’s as Informed by Multiple Cohorts, Machine Learning and External Validation
Juan Li, Kelsey Grimes, Joseph Saade, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Drug repurposing screens identify compounds that inhibit α-synuclein oligomers' membrane disruption and block antibody interactions
Arun Kumar Somavarapu, Giulia Kleijwegt, Madhu Nagaraj, et al.
Chemical Science (2023) Vol. 14, Iss. 11, pp. 3030-3047
Open Access | Times Cited: 2
AAV-mediated expression of a new conformational anti-aggregated α-synuclein antibody prolongs survival in a genetic model of α-synucleinopathies
Matthias Düchs, Dragica Blazevic, Philipp Rechtsteiner, et al.
npj Parkinson s Disease (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 2
Targeting α‐Synuclein: A Further Viewpoint
Anthony E. Lang
Movement Disorders (2023) Vol. 38, Iss. 4, pp. 715-716
Closed Access
Clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration: a quantitative systems pharmacology model analysis
Hugo Geerts, Silke Bergeler, Mike Walker, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top